Resencatinib (HS-10365) has demonstrated encouraging and durable antitumor efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) gene fusions[1].
Resencatinib exhibits favorable tolerability and a manageable safety profile[1].
Given its outstanding performance in efficacy and safety, resencatinib is expected to provide a novel treatment option for patients with locally advanced or metastatic NSCLC positive for RET gene fusions[1].
December 10, 2025
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced that the encouraging results of resencatinib，a highly selective RET receptor tyrosine kinase inhibitor, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions were presented in a poster session at the ESMO ASIA Congress 2025 (December 05-07, Singapore).
Details of the poster are as follows:
The HS-10365-101 study (NCT05207787) is a multicenter, open-label Phase Ⅰ/Ⅱ clinical trial designed as a "basket trial," aiming to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and efficacy of orally administered resencatinib. Preliminary data from the Phase Ⅰ portion were previously presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. At this year’s ESMO ASIA Congress, updated results from the Phase II portion—with a larger sample size and longer follow-up duration—were released, further validating the clinical value of resencatinib in patients with locally advanced or metastatic NSCLC harboring RET fusions.
Study results showed:
Significant Efficacy: A total of 326 patients (data cutoff: Jan 18, 2025) with RET-altered advanced solid tumors were treated with resencatinib at 160mg twice daily (BID) orally in the Phase II study. Among them, 75 patients were in Cohort 1 (locally advanced or metastatic NSCLC harboring RET fusions who progressed after platinum-containing chemotherapy combined with or sequential to PD-[L]1 inhibitor therapy) and 60 patients in Cohort 2 (treatment-naive locally advanced or metastatic NSCLC harboring RET fusions). Efficacy results for Cohort 1 and Cohort 2 as assessed by the Independent Review Committee (IRC) are as follows: confirmed Objective Response Rate (ORR) was 80.0% and 83.3%, respectively; Disease Control Rate (DCR) was 96.0% and 93.3%, respectively; and 12-month Progression-Free Survival (PFS) rate was 81.1% and 79.3%, respectively.
Favorable Tolerability: During the study, the most common treatment-emergent adverse events (TEAEs) with resencatinib monotherapy were increased alanine aminotransferase (ALT; 64.7%), increased aspartate aminotransferase (AST; 64.1%), and decreased white blood cell (WBC) count (45.4%). The vast majority of TEAEs were controllable and manageable, with only 4.9% of patients discontinuing treatment due to TEAEs. No new safety signals were identified, further validating the safety of resencatinib for clinical application.
Conclusions: The study results demonstrate that resencatinib exhibits significant and sustainable antitumor efficacy, as well as favorable and manageable safety profile, in both treatment-naive and pretreated patients with locally advanced or metastatic NSCLC harboring RET fusions. It may provide another new treatment option for this patient population.
About resencatinib (HS-10365)
Resencatinib (HS-10365) is a Class 1 innovative drug independently developed by the Group. As a small-molecule, highly selective RET receptor tyrosine kinase inhibitor, it can act directly on intracellular protein tyrosine kinases, bind competitively with ATP, and inhibit tyrosine kinase phosphorylation, thereby effectively controlling tumor growth. Previously, the New Drug Application (NDA) for resencatinib was accepted by the National Medical Products Administration (NMPA) of China, for the treatment of adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
About NSCLC
Approximately 787,000 new lung cancer cases are diagnosed annually in China, among which RET fusion-positive patients account for 1% to 2% of all lung cancer cases — translating to around 11,000 new RET gene-positive lung cancer patients each year in the country[2-4]. Currently, there remains a significant unmet clinical need for specific RET-targeted therapies in China. Although several highly selective RET inhibitors have been recommended in clinical guidelines[5], additional novel treatment options are still required to further improve drug accessibility.
About ESMO Asia
ESMO Asia Congress 2025 will be held from December 5-7, 2025 in the Republic of Singapore. The congress serves as a vital platform to advance cancer care through the latest scientific discoveries, innovative therapies, and evolving clinical practices. Whether you’re a clinician, researcher, or healthcare provider, this gathering offers a front-row seat to the future of oncology.
About Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and autoimmunity. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
Statements
1. This announcement is intended for healthcare professionals only and not for advertising purposes.
2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.
3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.
4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
References
1. Zhou Z, Wang Q, Wu L, et al. Resencatinib (HS-10365) in RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC): Updated results [poster 983P]. Presented at: 2025 ESMO Asia Congress; December 5-7, 2025; Singapore.
2. Subbiah V, Yang D, Velcheti V, et al. State-of-the-Art Strategies for Targeting RET -Dependent Cancers. J Clin Oncol. 2020,38(11):1209-1221.
3. Zhang K, Chen H, Wang Y, et al. Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients. Oncol Res. 2019, 27(5):575-582.
4. Zheng R S, Sun K X, Zhang S W, et al. Analysis of cancer incidence and mortality in China, 2015[J]. Chinese Journal of Oncology, 2019, 41(1):19-28.
5. Chinese Society of Clinical Oncology (CSCO). Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2025).
